Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status Not Available
ATC Code Not Available
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
NDC Product Code 17337-0082; 30007-838; 42291-073; 60687-455; 69238-1165; 42291-024; 69238-1754; 54893-0070
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disuse syndrome08.01.03.0670.001471%Not Available
Quality of life decreased13.18.01.0130.002942%Not Available
Spinal pain17.10.01.020;; Available
Enzyme level increased13.04.02.0150.001471%Not Available
Internal haemorrhage24.07.01.0720.003677%Not Available
Thyroid hormones decreased13.10.06.0170.001471%Not Available
Hyperosmolar hyperglycaemic state17.02.04.020;; Available
The 22th Page    First    Pre   22    Total 22 Pages